Some ligand-modified drug-loaded nanocarriers have also been used for the treatment of VM, such as cell-penetrating peptide R8 and PTDHIV-1, ligand targeting to BBB like MAN and cRGD, targeting to receptors which are highly expressed in tumor endothelial vessels and(or) VM channels like K237 and VEGF-PE38, peptides targeting to cancer cells or cancer stem cells like DQA and CVNHPAFAC-NH2. Here, VEGFA is linked to cancer.